RAPT Therapeutics, Inc.
RAPT
$0.906
-$0.0151-1.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 24.21% | -3.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 175.24% | -32.53% | |||
| Operating Income | -175.24% | 32.53% | |||
| Income Before Tax | -188.89% | 33.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -188.89% | 33.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -188.89% | 33.37% | |||
| EBIT | -175.24% | 32.53% | |||
| EBITDA | -177.96% | 32.85% | |||
| EPS Basic | -140.71% | 33.43% | |||
| Normalized Basic EPS | -143.13% | 33.43% | |||
| EPS Diluted | -140.71% | 33.43% | |||
| Normalized Diluted EPS | -143.13% | 33.43% | |||
| Average Basic Shares Outstanding | 20.01% | 0.09% | |||
| Average Diluted Shares Outstanding | 20.01% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||